Abstract
The biodistribution and pharmacokinetics of vanadium following i.p. administration of vanadocene dichloride (VDC), a representative of a new class of organometallic anticancer agents, is reported for Strain A mice. A convenient flameless atomic absorption spectroscopic assay is described and is used to determine kinetic profiles for vanadium in blood, kidney, liver, small intestine and brain tissue for times up to 24 h after administration. For a VDC dose of 80 mg/kg, vanadium concentration decreases rapidly from both the blood and small intestine, and the data can be fit to a phenomenological exponential function (blood: t 1 2 = 118 ± 43 min; small intestine: t 1 2(α) = 18.10 ± 0.14 min, t 1 2(β) = 341 ± 45 min). In contrast, vanadium accumulates in both the kidney and liver up to a maximal concentration (1.12 ± 0.06 mM and 0.56 ± 0.06 mM after 12 and 8 h, respectively), and is then excreted with estimated half-lives of 7.9 ± 0.7 and 12.1 ± 0.1 h, respectively. No detectable levels of vanadium are found in the brain tissue over the temporal course of the experiment. These results are compared to previous mammalian studies with cis-dichlorodiammineplatinum(II) (CDDP) and related 'second generation' platinum derivatives; there are both qualitative similarities between the vanadium and platinum systems as well as important quantitative differences.
| Original language | English |
|---|---|
| Pages (from-to) | 45-54 |
| Number of pages | 10 |
| Journal | Chemico-Biological Interactions |
| Volume | 56 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Dec 17 1985 |
Fingerprint
Keywords
- Vanadocene dichloride - Biodistribution - Pharmacokinetics - Anti-tumor agent - Mice
ASJC Scopus subject areas
- Toxicology
Cite this
Biodistribution and pharmacokinetics of vanadium following intraperitoneal administration of vanadocene dichloride to mice. / Toney, Jeffrey H.; Murthy, M. Satya; Marks, Tobin J.
In: Chemico-Biological Interactions, Vol. 56, No. 1, 17.12.1985, p. 45-54.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biodistribution and pharmacokinetics of vanadium following intraperitoneal administration of vanadocene dichloride to mice
AU - Toney, Jeffrey H.
AU - Murthy, M. Satya
AU - Marks, Tobin J
PY - 1985/12/17
Y1 - 1985/12/17
N2 - The biodistribution and pharmacokinetics of vanadium following i.p. administration of vanadocene dichloride (VDC), a representative of a new class of organometallic anticancer agents, is reported for Strain A mice. A convenient flameless atomic absorption spectroscopic assay is described and is used to determine kinetic profiles for vanadium in blood, kidney, liver, small intestine and brain tissue for times up to 24 h after administration. For a VDC dose of 80 mg/kg, vanadium concentration decreases rapidly from both the blood and small intestine, and the data can be fit to a phenomenological exponential function (blood: t 1 2 = 118 ± 43 min; small intestine: t 1 2(α) = 18.10 ± 0.14 min, t 1 2(β) = 341 ± 45 min). In contrast, vanadium accumulates in both the kidney and liver up to a maximal concentration (1.12 ± 0.06 mM and 0.56 ± 0.06 mM after 12 and 8 h, respectively), and is then excreted with estimated half-lives of 7.9 ± 0.7 and 12.1 ± 0.1 h, respectively. No detectable levels of vanadium are found in the brain tissue over the temporal course of the experiment. These results are compared to previous mammalian studies with cis-dichlorodiammineplatinum(II) (CDDP) and related 'second generation' platinum derivatives; there are both qualitative similarities between the vanadium and platinum systems as well as important quantitative differences.
AB - The biodistribution and pharmacokinetics of vanadium following i.p. administration of vanadocene dichloride (VDC), a representative of a new class of organometallic anticancer agents, is reported for Strain A mice. A convenient flameless atomic absorption spectroscopic assay is described and is used to determine kinetic profiles for vanadium in blood, kidney, liver, small intestine and brain tissue for times up to 24 h after administration. For a VDC dose of 80 mg/kg, vanadium concentration decreases rapidly from both the blood and small intestine, and the data can be fit to a phenomenological exponential function (blood: t 1 2 = 118 ± 43 min; small intestine: t 1 2(α) = 18.10 ± 0.14 min, t 1 2(β) = 341 ± 45 min). In contrast, vanadium accumulates in both the kidney and liver up to a maximal concentration (1.12 ± 0.06 mM and 0.56 ± 0.06 mM after 12 and 8 h, respectively), and is then excreted with estimated half-lives of 7.9 ± 0.7 and 12.1 ± 0.1 h, respectively. No detectable levels of vanadium are found in the brain tissue over the temporal course of the experiment. These results are compared to previous mammalian studies with cis-dichlorodiammineplatinum(II) (CDDP) and related 'second generation' platinum derivatives; there are both qualitative similarities between the vanadium and platinum systems as well as important quantitative differences.
KW - Vanadocene dichloride - Biodistribution - Pharmacokinetics - Anti-tumor agent - Mice
UR - http://www.scopus.com/inward/record.url?scp=0022405633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022405633&partnerID=8YFLogxK
U2 - 10.1016/0009-2797(85)90038-9
DO - 10.1016/0009-2797(85)90038-9
M3 - Article
VL - 56
SP - 45
EP - 54
JO - Chemico-Biological Interactions
JF - Chemico-Biological Interactions
SN - 0009-2797
IS - 1
ER -